Journal of Clinical Oncology, Vol 11, 1866-1872, Copyright © 1993 by American Society of Clinical Oncology

ARTICLES

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

R Grilli, AD Oxman and JA Julian
Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada.

PURPOSE: To estimate the impact of chemotherapy on survival of patients with advanced non-small-cell lung cancer (NSCLC). METHODS: Randomized controlled trials (RCTs) published in the English-language medical literature between 1970 and 1991 were identified through MEDLINE and the reference lists of relevant articles. Six RCTs that accounted for 635 patients and compared first-line chemotherapy with supportive care in advanced NSCLC and reported survival up to at least 1 year were identified. Cumulative proportions of survival at 3, 6, 9, and 12 months for chemotherapy and control groups were derived from survival curves. RESULTS: Within each study, the effect of chemotherapy was estimated with a pooled relative risk (RR) across the four 3-month periods. An overall estimate of the RR of death at 1 year (RRM-H) was then calculated and a survival curve for chemotherapy-treated patients was constructed applying the pooled estimate of the RR (RRW) for each 3- month period. Overall, chemotherapy was associated with a 24% (95% confidence interval [CI], 13% to 34%) reduction in the probability of death when compared with supportive care. However, the effect of treatment appeared to decrease significantly after the first 6 months from therapy inception and the mean potential gain in survival, as compared with supportive care, was approximately 6 weeks (95% CI, 1 to 10). CONCLUSION: Chemotherapy is effective in the treatment of advanced NSCLC, but its impact on the length of survival is limited. Future RCTs should still include an untreated control group and should measure quality of life in addition to survival.

This article has been cited by other articles:

				J. O. Park, S.-W. Kim, J. S. Ahn, C. Suh, J. S. Lee, J. S. Jang, E. K. Cho, S. H. Yang, J.-H. Choi, D. S. Heo, et al. Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non Small-Cell Lung Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5233 - 5239. [Abstract] [Full Text] [PDF]

				P Comella, G Filippelli, G De Cataldis, B Massidda, G Frasci, L Maiorino, C Putzu, S Mancarella, S Palmeri, R Cioffi, et al. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101) Ann. Onc., February 1, 2007; 18(2): 324 - 330. [Abstract] [Full Text] [PDF]

				C. Belani, S Dakhil, D. Waterhouse, C. Desch, D. Rooney, R. Clark, M. Monberg, Z Ye, and C. Obasaju Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer Ann. Onc., January 1, 2007; 18(1): 110 - 115. [Abstract] [Full Text] [PDF]

				J. Nemunaitis, R. O. Dillman, P. O. Schwarzenberger, N. Senzer, C. Cunningham, J. Cutler, A. Tong, P. Kumar, B. Pappen, C. Hamilton, et al. Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non-Small-Cell Lung Cancer J. Clin. Oncol., October 10, 2006; 24(29): 4721 - 4730. [Abstract] [Full Text] [PDF]

				S. Niho, K. Kubota, K. Goto, K. Yoh, H. Ohmatsu, R. Kakinuma, N. Saijo, and Y. Nishiwaki First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Phase II Study J. Clin. Oncol., January 1, 2006; 24(1): 64 - 69. [Abstract] [Full Text] [PDF]

				S. K. Williamson, J. J. Crowley, P. N. Lara Jr, J. McCoy, D. H.M. Lau, R. W. Tucker, G. M. Mills, and D. R. Gandara Phase III Trial of Paclitaxel Plus Carboplatin With or Without Tirapazamine in Advanced Non-Small-Cell Lung Cancer: Southwest Oncology Group Trial S0003 J. Clin. Oncol., December 20, 2005; 23(36): 9097 - 9104. [Abstract] [Full Text] [PDF]

				C. X. Ma, S. Nair, S. Thomas, S. J. Mandrekar, D. A. Nikcevich, K. M. Rowland, T. R. Fitch, H. E. Windschitl, S. L. Hillman, S. E. Schild, et al. Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., September 1, 2005; 23(25): 5929 - 5937. [Abstract] [Full Text] [PDF]

				K. Matsui, T. Hirashima, T. Nitta, M. Kobayashi, Y. Ogata, M. Furukawa, S. Kudoh, N. Yoshimura, T. Mukohara, S. Yamauchi, et al. A Phase I/II Study Comparing Regimen Schedules of Gemcitabine and Docetaxel in Japanese Patients with Stage IIIB/IV Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., April 1, 2005; 35(4): 181 - 187. [Abstract] [Full Text] [PDF]

				F. Waechter, J. Passweg, M. Tamm, M. Brutsche, R. Herrmann, and M. Pless Significant Progress in Palliative Treatment of Non-small Cell Lung Cancer in the Past Decade Chest, March 1, 2005; 127(3): 738 - 747. [Abstract] [Full Text] [PDF]

				C. Delbaldo, S. Michiels, N. Syz, J.-C. Soria, T. Le Chevalier, and J.-P. Pignon Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non-Small-Cell Lung Cancer: A Meta-analysis JAMA, July 28, 2004; 292(4): 470 - 484. [Abstract] [Full Text] [PDF]

				N. Hanna, F. A. Shepherd, F. V. Fossella, J. R. Pereira, F. De Marinis, J. von Pawel, U. Gatzemeier, T. C. Y. Tsao, M. Pless, T. Muller, et al. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy J. Clin. Oncol., May 1, 2004; 22(9): 1589 - 1597. [Abstract] [Full Text] [PDF]

				A. Spira and D. S. Ettinger Multidisciplinary Management of Lung Cancer N. Engl. J. Med., January 22, 2004; 350(4): 379 - 392. [Full Text] [PDF]

				S.-Y. Song, W. S. Kim, K. Kim, C. W. Jung, Y. H. Im, H. J. Kim, W. K. Kang, H. G. Lee, O J. Kwon, C. H. Rhee, et al. Vinorelbine, Ifosfamide, and Cisplatin Combination as Salvage Chemotherapy in Advanced Non-Small Cell Lung Cancer Jpn. J. Clin. Oncol., October 1, 2003; 33(10): 509 - 513. [Abstract] [Full Text] [PDF]

				C. P. Belani, J. Barstis, M. C. Perry, R. V. La Rocca, S. R. Nattam, D. Rinaldi, R. Clark, and G. M. Mills Multicenter, Randomized Trial for Stage IIIB or IV Non-Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or Observation J. Clin. Oncol., August 1, 2003; 21(15): 2933 - 2939. [Abstract] [Full Text] [PDF]

				M. A. Socinski, D. E. Morris, G. A. Masters, and R. Lilenbaum Chemotherapeutic Management of Stage IV Non-small Cell Lung Cancer Chest, January 1, 2003; 123(1_suppl): 226S - 243S. [Abstract] [Full Text] [PDF]

				V. Lorusso, E. Crucitta, N. Panza, N. Silvestris, M. Guida, F. Carpagnano, S. Mancarella, D. Sambiasi, and M. De Lena Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer Ann. Onc., December 1, 2002; 13(12): 1862 - 1867. [Abstract] [Full Text] [PDF]

				J. H. Schiller, D. Harrington, C. P. Belani, C. Langer, A. Sandler, J. Krook, J. Zhu, D. H. Johnson, and the Eastern Cooperative Oncology Group Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer N. Engl. J. Med., January 10, 2002; 346(2): 92 - 98. [Abstract] [Full Text] [PDF]

				Y.-M. Chen, R.-P. Perng, Y.-C. Lee, J.-F. Shih, C.-S. Lee, C.-M. Tsai, and J. Whang-Peng Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated Ann. Onc., January 1, 2002; 13(1): 108 - 115. [Abstract] [Full Text] [PDF]

				F. W. Grannis Jr A response to ""Clinical Trials in Lung Cancer: Truth, Justice, and the American Way"" Ann. Thorac. Surg., October 1, 2001; 72(4): 1438 - 1438. [Full Text] [PDF]

				J.-Y. Han, K. W. Kim, J. A. Kim, J. H. Kang, J.-Y. Jin, Y. S. Hong, S. Y. Park, J.-S. Song, J. W. Park, H.-K. Kim, et al. A Phase II Study of a Daily 4 Schedule of Vinorelbine Plus Cisplatin for Advanced Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., October 1, 2000; 30(10): 435 - 439. [Abstract] [Full Text] [PDF]

				J.-M. Berthelot, B. P. Will, W. K. Evans, D. Coyle, C. C. Earle, and L. Bordeleau Decision Framework for Chemotherapeutic Interventions for Metastatic Non-Small-Cell Lung Cancer J Natl Cancer Inst, August 16, 2000; 92(16): 1321 - 1329. [Abstract] [Full Text] [PDF]

				F. V. Fossella, R. DeVore, R. N. Kerr, J. Crawford, R. R. Natale, F. Dunphy, L. Kalman, V. Miller, J. S. Lee, M. Moore, et al. Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non-Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens J. Clin. Oncol., June 12, 2000; 18(12): 2354 - 2362. [Abstract] [Full Text] [PDF]

				D. H. Johnson Locally Advanced, Unresectable Non-Small Cell Lung Cancer : New Treatment Strategies Chest, April 1, 2000; 117(4_suppl_1): 123S - 126S. [Abstract] [Full Text] [PDF]

				P. Bonomi, K. Kim, D. Fairclough, D. Cella, J. Kugler, E. Rowinsky, M. Jiroutek, and D. Johnson Comparison of Survival and Quality of Life in Advanced Non-Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial J. Clin. Oncol., February 1, 2000; 18(3): 623 - 623. [Abstract] [Full Text] [PDF]

				V. Lorusso, F. Carpagnano, G. Frasci, N. Panza, G. Di Rienzo, M. L. Cisternino, G. Napoli, S. Orlando, S. Cinieri, C. Brunetti, et al. Phase I/II Study of Gemcitabine Plus Vinorelbine as First-Line Chemotherapy of Non-Small-Cell Lung Cancer J. Clin. Oncol., January 14, 2000; 18(2): 405 - 405. [Abstract] [Full Text] [PDF]

				C. C. Earle and G. A. Wells An Assessment of Methods to Combine Published Survival Curves Med Decis Making, January 1, 2000; 20(1): 104 - 111. [Abstract] [PDF]

				A. Hiraki, T. Kaneshige, K. Kiura, H. Ueoka, H. Yamane, M. Tanaka, and M. Harada Loss of HLA Haplotype in Lung Cancer Cell Lines: Implications for Immunosurveillance of Altered HLA Class I/II Phenotypes in Lung Cancer Clin. Cancer Res., April 1, 1999; 5(4): 933 - 936. [Abstract] [Full Text] [PDF]

				R. V. Iaffaioli, A. Tortoriello, G. Facchini, F. Caponigro, M. Gentile, N. Marzano, A. Gravina, P. Dimitri, G. Costagliola, A. Ferraro, et al. Phase I-II Study of Gemcitabine and Carboplatin in Stage IIIB-IV Non–Small-Cell Lung Cancer J. Clin. Oncol., March 1, 1999; 17(3): 921 - 921. [Abstract] [Full Text] [PDF]

				C. P. Belani, C. M. Kearns, E. G. Zuhowski, K. Erkmen, D. Hiponia, D. Zacharski, C. Engstrom, R. K. Ramanathan, M. J. Capozzoli, J. Aisner, et al. Phase I Trial, Including Pharmacokinetic and Pharmacodynamic Correlations, of Combination Paclitaxel and Carboplatin in Patients With Metastatic Non–Small-Cell Lung Cancer J. Clin. Oncol., February 1, 1999; 17(2): 676 - 676. [Abstract] [Full Text] [PDF]

				F. Cardenal, M. P. Lopez-Cabrerizo, A. Anton, V. Alberola, B. Massuti, A. Carrato, I. Barneto, M. Lomas, M. Garcia, P. Lianes, et al. Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer J. Clin. Oncol., January 1, 1999; 17(1): 12 - 12. [Abstract] [Full Text] [PDF]

				G. Silvestri, R. Pritchard, and H G. Welch Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews BMJ, September 19, 1998; 317(7161): 771 - 775. [Abstract] [Full Text] [PDF]

				N. M. Ellison Palliative chemotherapy American Journal of Hospice and Palliative Medicine, March 1, 1998; 15(2): 93 - 103. [PDF]

				{blacktriangledown}Gemcitabine for lung cancer DTB, September 1, 1996; 34(9): 71 - 72. [Abstract] [Full Text] [PDF]

				V. Cocquyt, W. De Neve, S. J.-P. Van Belle, N. Chanarin, N. E. Mills, C. L. Fishman, D. R. Jacobson, S.-A. McLachlan, M. Stockler, and R. Rosell Chemotherapy plus Surgery versus Surgery Alone in Non-Small-Cell Lung Cancer N. Engl. J. Med., June 16, 1994; 330(24): 1756 - 1757. [Full Text]